In silico cancer modeling: is it ready for prime time?

Authors:

Abstract
In the era of personalized, systems-driven medicine, computational orin silicomodeling and the simulation of disease processes is becoming increasingly important for hypothesis generation and data integration in both experiments and clinics alike. The authors of this Review discuss selected studies on modeling malignant brain tumors and the implications for clinical practice, including trial design and outcome prediction. At the dawn of the era of personalized, systems-driven medicine, computational or in silico modeling and the simulation of disease processes is becoming increasingly important for hypothesis generation and data integration in both experiments and clinics alike. Arguably, the use of these techniques is nowhere more visible than in oncology. To illustrate the field's vast potential, as well as its current limitations, we briefly review selected studies on modeling malignant brain tumors. Implications for clinical practice, and for clinical trial design and outcome prediction, are also discussed.

This publication has 70 references indexed in Scilit: